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Background: Segmental Xp22.2 monosomy or a heterozygous HCCS mutation is associated with the microphthalmia
with linear skin defects (MLS) or MIDAS (microphthalmia, dermal aplasia, and sclerocornea) syndrome, an X-linked
disorder with male lethality. HCCS encodes the holocytochrome c-type synthase involved in mitochondrial oxidative
phosphorylation (OXPHOS) and programmed cell death.
Methods: We characterized the X-chromosomal abnormality encompassing HCCS or an intragenic mutation in this
gene in six new female patients with an MLS phenotype by cytogenetic analysis, fluorescence in situ hybridization,
sequencing, and quantitative real-time PCR. The X chromosome inactivation (XCI) pattern was determined and clinical
data of the patients were reviewed.
Results: Two terminal Xp deletions of ≥11.2 Mb, two submicroscopic copy number losses, one of ~850 kb and
one of ≥3 Mb, all covering HCCS, 1 nonsense, and one mosaic 2-bp deletion in HCCS are reported. All females had a
completely (>98:2) or slightly skewed (82:18) XCI pattern. The most consistent clinical features were microphthalmia/
anophthalmia and sclerocornea/corneal opacity in all patients and congenital linear skin defects in 4/6. Additional
manifestations included various ocular anomalies, cardiac defects, brain imaging abnormalities, microcephaly, postnatal
growth retardation, and facial dysmorphism. However, no obvious clinical sign was observed in three female carriers
who were relatives of one patient.
Conclusion: Our findings showed a wide phenotypic spectrum ranging from asymptomatic females with an HCCS
mutation to patients with a neonatal lethal MLS form. Somatic mosaicism and the different ability of embryonic cells to
cope with an OXPHOS defect and/or enhanced cell death upon HCCS deficiency likely underlie the great variability in
phenotypes.
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The microphthalmia with linear skin defects (MLS) syn-
drome (MIM 309801) is a rare X-linked neurodevelop-
mental disorder with male in utero lethality. The main
clinical characteristics are uni- or bilateral microphthal-
mia and linear aplastic skin lesions which are usually
limited to face and neck and develop into healed hyper-
pigmented areas with age. Additional features such as
sclerocornea, corneal opacities, congenital heart defects,
microcephaly, intellectual disability and agenesis of the
corpus callosum have been observed less frequently [1].
The majority of MLS-affected patients carry a cytoge-
netically visible deletion or an unbalanced translocation
leading to Xp22.2 monosomy [1]. After the minimal crit-
ical region of MLS syndrome had been defined to en-
compass the genes MID1, HCCS and ARHGAP6 in 1994
[2,3], heterozygous intragenic mutations in HCCS were
identified as causative in 2006 [4]. Since then, only one
additional HCCS missense mutation has been described
in a sporadic female patient with microphthalmia and
sclerocornea of both eyes [5]. HCCS encodes the holocyto-
chrome c-type synthase that is involved in mitochondrial
oxidative phosphorylation (OXPHOS) where it catalyzes
the incorporation of heme moieties to cytochrome c and
cytochrome c1 [6,7]. Cytochrome c1 is an integral compo-
nent of complex III of the mitochondrial respiratory chain
(MRC), while cytochrome c functions as an electron shut-
tle between complexes III and IV [8]. Complementation
studies in yeast revealed severely impaired OXPHOS upon
HCCS deficiency [6]. Recently, mutations in another gene,
COX7B in chromosome band Xq21.1, encoding a struc-
tural subunit of cytochrome c oxidase (complex IV) in-
volved in OXPHOS, have been identified in females with
an MLS phenotype [9].
A high inter- and intrafamiliar phenotypic variability has
been described in females with MLS syndrome [4,10-12].
Patients with an intragenic mutation or a (submicro-
scopic) deletion covering HCCS can show the full-blown
MLS phenotype associated with other anomalies, the clas-
sical combination of microphthalmia/anophthalmia and
linear skin defects, isolated ocular manifestations, aplastic
skin areas restricted to face and neck with no additional
abnormalities or no symptoms at all [4,5,10,11,13-15]. As
possible explanations for this great clinical variability som-
atic mosaicism for the mutation and the degree of skewed
X chromosome inactivation (XCI) in different tissues have
been discussed [4,14,16,17].
Since 2007, we ascertained six novel female patients
with a clinical diagnosis of MLS syndrome. Here we
summarize the clinical and molecular data of these pa-
tients who were found to have different alterations involv-
ing the HCCS gene, ranging from classical chromosomal
rearrangements of the Xp22 region to point mutations.
We discuss different genetic mechanisms which protectfemales with an HCCS alteration from developing MLS-
typical clinical features.
Methods
Patients
The study was approved by the Ethics Committee of the
Medical Chamber of Hamburg (No. PV3585). We ob-
tained clinical data as well as blood, buccal swabs, lym-
phoblastoid cells and/or DNA samples from six patients
with a clinical diagnosis of MLS syndrome, who were
assessed by experienced clinical geneticists. The clinical
data and samples were obtained with informed consent,
including consent to use the photographs in this report.
Cytogenetic and fluorescence in situ hybridization (FISH)
analysis
Conventional karyotyping was performed on metaphase
spreads from peripheral blood lymphocytes by standard
procedures. We used the Xp subtelomeric ToTelVysion
probe (Abbott Molecular Inc, Des Plaines, IL, USA), the
Vysis Steroid Sulfatase Deficiency probe (Vysis LSI STS;
Abbott Molecular Inc) and the X centromere probe
(Poseidon Satellite Enumeration Probe (SE) X (DXZ1),
Kreatech Diagnostics, Amsterdam, NL) in FISH experi-
ments. The bacterial artificial chromosome (BAC) clone
RP11-163I1 (RPCI-11 human male BAC library) and fos-
mid clones (WIBR-2 human fosmid library [G248P8]) were
received from the BACPAC Resource Center, Children’s
Hospital Oakland, CA, USA. BAC and fosmid DNA was
prepared using the NucleoBond Xtra Midi kit (Macherey-
Nagel, Düren, Germany). BAC and fosmid DNA was la-
beled by nick translation using the CGH Nick Translation
Kit and Spectrum Green-dUTP and Spectrum Red-dUTP
(Vysis, Downers Grove, IL, USA), respectively, accord-
ing to the protocol provided. Chromosomes were coun-
terstained using 4′,6-diamidino-2-phenylindole (DAPI)
(Serva Feinbiochemica, Heidelberg, Germany) and mounted
in antifading solution (Vector Labs, Burlingame, CA,
USA). Slides were analysed with a Leica Axioscope fluor-
escence microscope. Images were merged using a cooled
CCD camera (Pieper, Schwerte, Germany) and CytoVision
software (Applied Imaging, San Jose, CA, USA).
Quantitative real-time polymerase chain reaction (qPCR)
qPCR of HCCS exons on genomic DNA was carried out
as described previously [18]. Primer sequences are avail-
able on request.
Sequencing of HCCS
DNA from whole blood, buccal swabs or lymphoblastoid
cells was isolated by standard procedures. The coding re-
gion of the HCCS gene (exons 2–7; GenBank accession
no. NM_005333.4) including flanking intronic sequences
was amplified from genomic DNA. Primer sequences and
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were directly sequenced using the ABI BigDye Termin-
ator Sequencing Kit (Applied Biosystems, Darmstadt,
Germany) and an automated capillary sequencer (ABI
3500; Applied Biosystems). Sequence electropherograms
were analysed using Sequence Pilot software (JSI Medical
Systems, Kippenheim, Germany).
Microsatellite analysis
Where mutations were shown to have arisen de novo, we
verified declared relationships by genotyping both par-
ents and the patient at fifteen short tandem repeat (STR)
loci and Amelogenin using the The AmpFLSTR Identifiler
PCR Amplification Kit (Applied Biosystems). DNA iso-
lated from lymphocytes and the lymphoblastoid cell line
of patient 3 was genotyped using the The AmpFLSTR
Identifiler PCR Amplification Kit.
Cloning of a mutation bearing PCR product to analyse
for mosaicism
We cloned the amplicon of HCCS exon 6 in the pCR2.1
TOPO TA Cloning® Vector (Invitrogen, Karlsruhe, Germany).
We picked bacterial clones and amplified them using
standard protocols to identify those that contained a
copy of the amplicon. We sequenced 138 PCR products
to permit identification of those clones to contain mu-
tation or wild-type bearing amplicons using the ABI
BigDye Terminator Sequencing Kit (Applied Biosystems)
and the automated capillary sequencer ABI 3500 (Applied
Biosystems). Sequences were assembled and compared
using the software SeqMan (DNASTAR, Madison, WI,
USA).
X chromosome inactivation analysis
The methylation status of the AR, PGK1 or MAOA locus
was examined by already described assays [19-21]. We
modified the protocols as follows. For each DNA sam-
ple, two reactions were prepared. In the first reaction,
400 ng of DNA was digested with 8 U HpaII in a total
volume of 10 μl for 40 min at 37°C. In the second reac-
tion, the same amount of DNA was incubated with the
reaction buffer but without restriction enzyme. The
digested and undigested fractions were submitted to
PCR using fluorochrome-coupled primers (AR: forward
primer: 5′-[6FAM]CTTTCCAGAATCTGTTCCAG-3′ and
reverse primer: 5′-AAGGTTGCTGTTCCTCATC-3′; PGK1:
forward primer: 5′-[6FAM]TGTTCCGCATTCTGCAAGC
C-3′ and reverse primer: 5′-TATCCTTTTGTGCAGGAA
CC-3′; MAOA: forward primer: 5′-AGTAATCCTTTCCA
GCTGCCGAC-3′ and reverse primer: 5′-[6FAM]TGCTTC
ATAAAGGGATTCTCTTTG-3′). PCR conditions are
available on request. For PGK1: PCR products were
digested with BstXI at 55°C for 3 h and the enzyme was
inactivated at 65°C for 20 min. For MAOA: PCRamplicons were precipitated with ethanol and 3 M
NaAc (pH 5.8), and the precipitate was dissolved in
H2O. After submitting the fraction to digestion with SacI
at 37°C for 1 h, the enzyme was inactivated at 65°C for
20 min. The resulting amplification products (AR locus)
or digested fractions (PGK1 and MAOA loci) were run on
an ABI 3500 automated sequencer and the peak areas
were calculated by GeneMapper Software v4.1 (Applied
Biosystems). To account for preferential allele amplifica-
tion, values for the digested DNA were normalized with
those for the undigested DNA of each proband. The XCI
pattern (expressed arbitrarily as a ratio of the smaller:
larger allele) was calculated by applying the previously
reported formula [22]: skewing = (d1/u1)/(d1/u1) + (d2/u2),
where d1 and d2 represent the two raw peak area
values of the digested sample, and u1 and u2 represent
the raw peak area values of the undigested sample. In
addition, one control male sample and one sample
from a female known to have a completely skewed pat-
tern of XCI (>98:2) were included in every batch of
samples, to control for complete digestion and amplifi-
cation efficiency.
X-inactivation testing in patient 3 was initiated at the
respective centre within routine diagnostics.Results
In the six female patients with typical clinical manifesta-
tions of MLS syndrome, we identified heterozygous alter-
ations of the HCCS gene. These comprised sequence-level
mutations as well as microdeletions and cytogenetically
visible deletions including multiple other genes (Table 1).Chromosomal analysis and FISH
Routine cytogenetic analysis was performed in patients 1
and 3–6 diagnosed with MLS syndrome and revealed an
apparently normal female karyotype in patients 1, 3, and 6.
Patients 4 and 5 showed a structurally abnormal karyotype
with 46,X,del(X)(p22) (Table 1). We confirmed the terminal
Xp deletion by FISH using BAC RP11-163I1 encompassing
the HCCS gene in patients 4 and 5 and a subtelomeric
Xp probe together with a probe covering the STS gene
(Xp22.32) in patient 4 (data not shown). The estimated
minimum size of the two deletions was ≥11.2 Mb. FISH with
the STS and X centromere probes on metaphase spreads of
the parents of patient 4 revealed the expected number
of signals (data not shown).
High resolution molecular karyotyping using Agilent
Human Genome CGH 44 K oligonucleotide arrays (Agilent,
Santa Clara, CA, USA) with the ISCA design (www.
iscaconsortium.org) was performed on a clinical basis in
patient 2 and revealed no disease-associated copy number
variant (data not shown).
Table 1 Collection of molecular and clinical data of 6 patients with MLS syndrome
Patients HCCS mutation XCIa Dermatologic
findings
Ocular findings
Microphthalmia/
anophthalmia
Sclerocornea/corneal
opacity
Others
1 ish del(X)(p22.2p22.2),
interstitial deletion
of ~850 kb including
HCCS inherited
100:0 ― bilateral microphthalmia bilateral sclerocornea gracile optic nerves and chiasma, bilateral
microcornea, ectopic pupil (right), coloboma iris
(right), anterior eye chamber defect7 years Dutch
2 c.589C > T (p.R197*)
de novo
98:2 linear skin defects on the neck microphthalmia (Peter’s anomaly with
adherence of iris on cornea and anterior
chamber) (right), anophthalmia (left)
unilateral sclerocornea
and corneal opacity
(right)
optic nerve hypoplasia (left)
Died at 4 months
French
3 c.[=/524_525delAG]
(p.[=/E175Vfs*30])
de novo
82:18 ― unilateral microphthalmia (left) unilateral sclerocornea
(left)
unilateral cornea plana (left)
3 years German
4 46,X,del(X)(p22)
de novo
100:0 linear skin defects on the face,
neck, hand (right) and foot
(left)
severe bilateral microphthalmia corneal opacity aphakia
4 years German
5 46,X,del(X)(p22)
de novo
100:0 linear skin defects on the face,
small hemangiomas on face,
neck and right hand
microphthalmia (left), anophthalmia (right) unilateral sclerocornea
(left)
―
10 years Greek
6 interstitial deletion
of ≥3 Mb including HCCSh
100:0 linear skin defects on the face bilateral microphthalmia bilateral sclerocornea ―
1 year Brazilian
Patients Cardiac defects CNS
anomalies
Microcephaly Developmental
delay/intellectual
disability
Facial
dysmorphism
Short stature Other anomalies
1 ― very mild delay in
myelination
― ― small deep-set eyes ― ―
7 years Dutch
2 ventricular tachycardia, poor
contraction of left ventricle,
histiocytoid cardiomyopathy,
eosinophilic cell infiltration
abnormal myelination,
hypoplastic corpus
callosum, absence of
septum pellucidum
― n.a. ― −3 SDb ―
Died at 4 months
French
3 ― n.d. ― mild motor delayc mild facial asymmetry,
prominent philtrum
― mild muscular hypotonia,
sacral dimple
3 years German
4 ― agenesis of corpus
callosum
−4.86 SDd + mild prognathism 48 cm (0.1 cm <3rd
centile)e; -3.33 SDd
―
4 years German
5 ― ― 49 cm
(3rd centile)f
+ long thin face, mild prognathism,
depressed nasal bridge,
microdontia, high palate, low-set
and posteriorly rotated ears
105 cm (3rd centile)g deafness (right), anal atresia
with ectopic anus and fistula,
clinodactyly of the
fifth finger
10 years Greek
6 ― ― ― ― ― 67 cmi intralesional absence of
sebaceous glands
(dermatoscopic examination)1 year Brazilian
Legends: n.a.: not applicable; n.d.: not determined; SD: standard deviation; ―: absent; +: present; a: determined in leukocytes; b: at the age of 3 months; c: at the age of 11 months; d: at the age of 3 years; e: at birth; f:
at the age of 7 years; g: at the age of 6 years; h: inheritance of the interstitial microdeletion could not be determined as the father was not available. i: at the age of 9 months.
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In patient 5, the large Xp deletion was confirmed by qPCR
of the selected HCCS exons 1, 3, 4, and 6 (Additional file 1:
Figure S1). Expected values were observed for the relative
copy number of the four HCCS exons in both parents of
patient 5 (Additional file 1: Figure S1) indicating that her
deletion occurred de novo.
To uncover a possible microdeletion covering HCCS, we
performed FISH with RP11-163I1 and detected only one
signal in patient 1 (III-1 in the pedigree of Figure 1A) sug-
gesting an interstitial Xp deletion. We delineated the
breakpoints by FISH with Xp22.2 fosmid clones (Figure 1B).
For the distal deletion breakpoint, two signals were ob-
tained for G248P86973A3, while only one signal was
detected for G248P89648H11 (Additional file 1: Figure S2).
To map the proximal deletion breakpoint, we used fos-
mid G248P82946A7 which gave only one signal, while
G248P8046H9 yielded two signals (Additional file 1:
Figure S2). Thus, patient 1 carried a ~850 kb microde-
letion covering the entire HCCS gene and part of the
neighboring genes MID1 and ARHGAP6 (ish del(X)
(p22.2p22.2)) (Figure 1B and Table 1). qPCR confirmed
that the relative copy number of HCCS exons 2–7 in pa-
tient 1 was comparable to a haploid sample (Additional
file 1: Figure S3). By FISH with BAC RP11-163I1 we de-
tected the Xp22.2 microdeletion in the healthy mother
(II-1 in Figure 1A) and the healthy maternal aunt of pa-
tient 1, too (II-2 in Figure 1A). In her healthy maternal
grandmother, routine cytogenetic analysis revealed three
X chromosomes in 25 analysed metaphases (data not
shown). To confirm triple X syndrome, we performed
FISH with RP11-163I1 in combination with the X centro-
mere probe and detected two signals for the BAC and
three for the centromere probe in 65 analysed metaphases
(I-1 in Figure 1A and data not shown). However, in seven
metaphases we found signals on two X chromosomes
for the centromere probe and one signal for the BAC
clone indicating mosaic trisomy X in patient’s 1 mater-
nal grandmother (data not shown). By analysing six
X-chromosomal microsatellite markers we confirmed
the presence of three alleles in this female (data not
shown). To summarize, patient’s 1 healthy maternal grand-
mother carried the ~850 kb microdeletion covering
HCCS on one of her X chromosomes, and she had a
mosaic form of triple X in her leukocytes (47,XXX.ish del
(X)(p22.2p22.2)(HCCS−)[65]/46,XX.ish del(X)(p22.2p22.2)
(HCCS−)[7]).
To analyse for the presence of a possible (submicro-
scopic) Xp22 deletion in patient 6 from Brazil, we had to
perform qPCR experiments as only DNA and no lympho-
cyte suspension culture was available. The relative copy
number of the selected HCCS exons 1, 3, 6 and 7 was
found to be comparable with a haploid sample in patient
6, while her mother yielded values comparable with adiploid sample (Figure 2A). A DNA sample of patient’s 6
father was not available. To estimate the approximate size
of the deletion, we selected genes located telomeric and
centromeric to HCCS and performed additional qPCRs.
We mapped the proximal breakpoint between the two
genes TLR7 and RAB9A and the distal breakpoint between
KAL1 and SHROOM2 (Figures 1B and 2B). The data dem-
onstrates a submicroscopic interstitial Xp deletion of a
minimum size of 3 Mb in patient 6 encompassing the en-
tire genes HCCS, MID1 and ARHGAP6 (Figure 1B).
Sequence analysis of HCCS
We Sanger-sequenced the coding exons 2–7 of HCCS in
patients 2 and 3. In patient 2, we identified the heterozy-
gous de novo nonsense mutation c.589C >T (p.R197*) in
exon 6 (Figure 3A) (paternity confirmed; data not shown).
In leukocyte-derived DNA of patient 3, we detected the 2-
bp deletion c.524_525delAG in exon 6 that results in a
frameshift and introduction of a premature termination
codon (p.E175Vfs*30) (Figure 3B). The sequence profile
showed slightly lower signals for the mutant variant super-
imposed on the wild-type sequence suggesting that the mu-
tation was present in the mosaic state (Figure 3B). To
confirm somatic mosaicism of the 2-bp deletion in HCCS
in patient 3, we amplified exon 6 from leukocyte-derived
DNA, cloned the amplicon and subjected a total of 138 in-
dividual E.coli colonies to PCR followed by sequencing. We
identified 102 wild-type alleles (73.9%) and 36 alleles with
the mutation c.524_525delAG (26.1%) demonstrating som-
atic mosaicism in patient 3 (data not shown). Thus, patient
3 had a mixed population of in vivo lymphocytes: ~52% of
lymphocytes carry the heterozygous c.524_525delAG muta-
tion and ~48% carry two wild-type HCCS alleles. We next
investigated DNA from two other cell types of patient 3
and sequenced HCCS exon 6 in DNA isolated from buccal
cells and a lymphoblastoid cell line (LCL). As shown in
Figure 3B, the peak height of the two sequence profiles
representing the two different HCCS alleles in patient 3 was
similar in buccal cell-derived DNA. In contrast, the sequen-
cing pattern of the mutant HCCS allele is not any more vis-
ible in DNA isolated from LCLs (Figure 3B). Absence of
the HCCS mutation in LCL-derived DNA suggested clonal
evolution of the lymphoblastoid cell line of patient 3
[23,24]. By genotyping 16 genetic markers we confirmed
that leukocyte- and LCL-derived DNA samples came from
the same person (patient 3) (data not shown). Together, the
data indicates that patient 3 carried a mosaic 2-bp deletion
(c.[=/524_525delAG]/p.[=/E175Vfs*30]) in HCCS. Absence
of the mutation in the parents is in line with somatic mosai-
cism in patient 3 (paternity confirmed; data not shown).
XCI analysis
The XCI pattern was determined in all patients. A totally
(100:0) and extremely skewed (98:2) XCI was detected at
Figure 1 Pedigree, FISH and X chromosome inactivation of patient 1 and three healthy female relatives. A. Pedigree of patient’s 1 family.
Patient 1 (III-1) is affected by MLS syndrome, while her mother (II-1), her maternal aunt (II-2) and her maternal grandmother (I-1) are asymptomatic.
FISH analysis with BAC RP11-163I1, spanning the HCCS gene on metaphase spreads of the four females revealed one signal in patient 1 (III-1), her
mother (II-1) and her aunt (II-2). For the maternal grandmother (I-1), two signals for RP11-163I1 and three signals for the X centromere probe DXZ1
were obtained. BAC RP11-163I1 and DXZ1 were labelled with Spectrum Green-dUTP. Arrows point to the wild-type X chromosome (WT X) and
the X chromosome with the microdeletion at Xp22.2 (del(X)). X chromosome inactivation was determined by analysing the methylation status
of the androgen receptor gene at Xq12. Predigestion of genomic DNA isolated from lymphocytes with and without HpaII is indicated by (+)
and (−), respectively. Representative electropherograms show the different AR alleles (designated as 1, 2, 3 and 4) in the four females. Females
II-1, II-2 and III-1 have extremely skewed X inactivation (upper electropherograms indicated with +). B. Physical map of part of the Xp22.3 and
Xp22.2 regions that are indicated by horizontal grey bars; Mbs and the telomere (tel) to centromere (cen) orientation are given. Arrows represent
selected genes in Xp22 and gene symbols are given; arrowheads indicate the 5′→ 3′ transcription direction of the genes. BAC RP11-163I1 (RP11
Human BAC Library) and four Xp22.2 fosmid (WIBR-2 Human Fosmid Library) clones are indicated by black bars and names are given. Interstitial
deletions found in patients 1 (P1) and 6 (P6) are depicted as horizontal black lines and the size of each deletion is given. Dotted and wavy lines
indicate that the deletion breakpoints were not fine-mapped.
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and 6 and patient 2, respectively (Table 1). As the inter-
stitial Xp22.2 deletion in patient 1 was also found inthree healthy family members, we also determined their
XCI pattern and found complete skewing (100:0) in leu-
kocytes of the mother and maternal aunt at the AR locus
Figure 2 Copy number analysis of HCCS and neighboring genes by quantitative real-time PCR in patient 6. A. Relative quantification of
copy number of HCCS exons 1, 3, 6 and 7 by qPCR on genomic DNA of patient 6 (black bars) and her mother (darkgrey bars) revealed values that
are comparable to a haploid sample (lightgrey bars) and a diploid sample (white bars), respectively. White, lightgrey and black bars represent the
mean ± SD of two independent experiments, each performed in duplicate. The darkgrey bars represent the mean of one experiment performed
in duplicate for each exon. B. Relative quantification of copy number of HCCS surrounding genes in patient 6. qPCR for KAL1 exon 8 and RAB9A
exon 3 on genomic DNA of patient 6 (black bars) revealed values that were comparable to a diploid sample (white bars), while those for SHROOM2
exon 6 and TLR7 exon 3 (black bars) were comparable with a haploid sample (lightgrey bars). Each bar represents the mean ± SD of at least two
experiments performed in duplicate.
Figure 3 HCCS sequence-level mutations in patients 2 and 3. A. Sequence electropherogram from genomic DNA of patient 2 showing part of
HCCS exon 6. Nucleotide triplets and encoded amino acids (one letter code) are indicated above the electropherogram. The red arrow points to the
double peak in the electropherogram showing heterozygosity for the nonsense mutation c.589C > T (p.R197*). B. Sequence electropherograms of part
of HCCS exon 6 from DNA isolated from leukocytes (top), buccal cells (middle) and the lymphoblastoid cell line (LCL; bottom) of patient 3. Nucleotide
triplets and encoded amino acids (one letter code) are shown for the wild-type and mutant allele above the electropherograms. The red arrow points
to the first double peak in the electropherogram indicating the start of the frameshift. In LCL-derived DNA only HCCS wild-type sequence was visible
in the electropherogram. Patient 3 carries the mosaic frameshift mutation c.[=/524_525delAG] / p.[=/E175Vfs*30] in HCCS.
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two X-chromosomal alleles prior and after restriction of
the DNA with the methylation sensitive enzyme HpaII
(Figure 1A) suggesting that two of the three X chromo-
somes carry the same AR allele and cannot be distin-
guished. Thus, a skewed XCI ratio possibly escaped
detection in this female. Patients 4 and 5 were not in-
formative at the AR locus. In patient 4, total XCI skew-
ing (100:0) was found at the MAOA locus (Table 1).
Similarly, patient 5 had an XCI ratio of 100:0 at the PGK
locus (Table 1). A slightly skewed XCI pattern (82:18)
was identified in leukocyte-derived DNA of patient 3 at
the FMR1 locus that is in line with a mosaic HCCS mu-
tation (Table 1).
Clinical data
Clinical data of the six index patients were reviewed
(Table 1). All were females aged between 4 months and
7 years at latest follow-up. Patient 2 died at the age of
4 months because of ventricular tachycardia and showed a
histiocytoid cardiomyopathy on post-mortem pathological
examination. The most consistent clinical features of all
patients were unilateral/bilateral microphthalmia/anoph-
thalmia and unilateral/bilateral sclerocornea/corneal opa-
city (Figure 4A, C-E, H and I). Additional ocular anomalies
were frequently observed (Table 1). Four girls (patients 2
and 4–6) had linear skin defects at least on the face and
neck (Figure 4A-C, F-I). Patient 4 presented with severe
erythematous linear skin lesions on her face after birth
(Figure 4F). They healed with age and developed to hyper-
pigmented areas (Figure 4G and H). Patients 1 and 3 did
not show congenital skin lesions (Figure 4D and E). No
cardiac defects except for those described in patient 2 were
reported. Brain imaging studies revealed delayed/abnormal
myelination in patients 1 and 2 and corpus callosum agen-
esis/hypoplasia in patients 2 and 4. Occipital frontal cir-
cumference in the low normal range or microcephaly was
observed in patients 4 and 5. Individuals 2, 4, 5 and 6 had
postnatal growth retardation of varying degree. Other
anomalies (sacral dimple, deafness, anal atresia with ec-
topic anus and fistula, clinodactyly of fifth finger, and lack
of sebaceous glands) were only seen in single patients.
Minor craniofacial dysmorphism was observed in patients
1, 3, 4 and 5 (Table 1 and Figure 4C, D, E, and H).
Discussion
We present molecular and clinical data of six new fe-
male patients with typical features of MLS syndrome
and a deletion or mutation involving HCCS. MLS syn-
drome was first described more than 20 years ago as a
disorder characterized by congenital linear skin lesions
and microphthalmia [25,26]. Since then a total of 62
cases with this clinical diagnosis have been reported
[1,27-31]. The majority of patients had a chromosomalabnormality resulting in monosomy for the Xp22.2 re-
gion. MLS syndrome mainly affects females, however,
ten males with an XX karyotype and Y-chromosomal
material or 46,XY and a mosaic inversion involving the
band Xp22.2 are known [11,15,29,32-36]. Finally, HCCS
turned out to be the culprit gene in Xp22.2 [4] and is
implicated in all chromosomal rearrangements reported
in MLS syndrome-affected individuals to date. The
known intragenic HCCS mutations comprise an 8.6-kb
copy number loss of part of the gene and the three point
mutations c.589C > T (p.R197*), c.649C > T (p.R217C)
and c.475G > A (p.E159K) [4,5]. By complementing a
Saccharomyces cerevisiae strain deficient for the HCCS
orthologue Cyc3p, the three sequence-level variants in
HCCS were found to be loss-of-function mutations af-
fecting MRC [4,5]. Additional evidence for implication
of mitochondrial dysfunction in MLS syndrome came
from the discovery of COX7B as the second gene for this
neurocutaneous disorder; it encodes a structural subunit
of MRC complex IV [9]. Deficiency of the COX7B or
HCCS orthologue in medaka was found to recapitulate
the MLS phenotype and demonstrated an essential func-
tion of the MRC complexes III and IV in human devel-
opment in general and central nervous system (CNS)
development in particular [9,37].
The HCCS mutations identified in the six patients re-
ported here represent the full spectrum of genetic alter-
ations leading to null alleles: two patients had the
common terminal Xp deletion with a size of ≥11.2 Mb
and two females carried a submicroscopic interstitial de-
letion, one of ~850 kb and the other of 3 Mb as minimum
size. The four deletions contain multiple genes including
HCCS. Only three cryptic interstitial deletions covering
HCCS have been reported in MLS-affected females so far:
One of >3 Mb [13], a second of 3.6 Mb [38] and a third of
185–220 kb [30]. The two remaining MLS-affected fe-
males carried de novo intragenic sequence changes, the
nonsense mutation c.589C > T (p.R197*) which seems to
represent a recurrent mutation [4], and the novel mosaic
2-bp deletion c.[=/524_525delAG] (p.[=/E175Vfs*30])].
Similar to other reports, we could not establish a genotype-
phenotype correlation and observed a high intra- and
interfamilial phenotypic variability in patients carrying
an HCCS alteration [1].
Unilateral/bilateral microphthalmia/anophthalmia and
sclerocornea/corneal opacity of one or both eyes were
found in all patients (Table 1). Other ocular findings in-
clude a wide variety of anomalies, such as microcornea,
coloboma, anterior chamber defect, optic nerve hypopla-
sia (this report) as well as retinal abnormalities, congeni-
tal glaucoma with total/peripheral anterior synechia, and
cataract [4,30]. Neonatal linear skin defects were seen in
four out of the six patients and varied in severity; pa-
tients 1 and 3 did not show any linear skin lesions or
Figure 4 Photographs of the six patients with MLS syndrome and a heterozygous HCCS mutation or Xp22 monosomy. A and B. Patient
2 died at the age of 4 months. She presented with microphthalmia and sclerocornea of the right eye and anophthalmia of the left eye (A). Linear
skin defects were observed on her neck (B). C. In the 7-year-old patient 5, linear skin defects and small hemangiomas were noted. She showed
microphthalmia and sclerocornea of the left eye and anophthalmia of the right eye. D. Microphthalmia and sclerocornea of both eyes were
present in patient 1, while linear skin defects were absent. E. In patient 3 (age 11 months), microphthalmia and sclerocornea of the left eye were
diagnosed. No linear skin defects were noted. F, G and H. Linear skin defects on the face of patient 4 were very prominent at birth (F, 4 days old), but
healed with age (3 weeks old in G and 2 years old in H). Severe bilateral microphthalmia was observed in the patient. I. Bilateral microphthalmia and
sclerocornea were observed in patient 6; she also had typical linear skin defects on her face (photographs submitted with written consent from the
patients’ legal guardians for publication in print and online).
van Rahden et al. Orphanet Journal of Rare Diseases 2014, 9:53 Page 9 of 13
http://www.ojrd.com/content/9/1/53scars on their face and neck (Figure 4D and E). This ob-
servation is not unusual as a few reported individuals
with Xp22 monosomy displayed eye abnormalities with
absence of skin defects [33,34,39]. Similarly, in patients
with a point mutation and small deletion in HCCS a var-
iety of ocular anomalies without skin defects have been
described [4,5]. To determine the phenotypic spectrum
in MLS syndrome, we nowadays have to distinguish be-
tween HCCS- and COX7B-mutation positive patients.
Interestingly, the four females with a COX7B mutation
did not display microphthalmia/anophthalmia, but vari-
able linear skin defects on the neck and face at birth [9].
Together, these data indicate that HCCS alterations
cause variable eye and skin abnormalities, while the lim-
ited data on patients with a COX7B mutation suggest
linear skin defects as the predominant feature.
We observed a wide range of additional clinical manifes-
tations, including CNS anomalies such as abnormal mye-
lination and hypoplasia/agenesis of corpus callosum and
microcephaly. Cardiac defects comprise ventricular tachy-
cardia, poor contraction of left ventricle, and histiocytoidcardiomyopathy. A few individuals had developmental
delay, short stature and facial dysmorphism (Table 1).
Rarely, hearing loss and anal atresia with ectopic anus
and fistula, as seen in patient 5 have also been observed
in other cases [13,35,40,41]. Patient 2 and one reported
girl [4] carried the HCCS nonsense mutation c.589C > T
(p.R197*). They show a remarkably similar full-blown
MLS phenotype with microphthalmia, sclerocornea,
linear erythrodermia, hypoplastic corpus callosum, and
absence of septum pellucidum. However, patient 2 was
more severely affected with anophthalmia and hypo-
plastic optic nerve of the left eye. She suffered from severe
cardiac problems and died at age 4 months. Histiocytoid
cardiomyopathy had been diagnosed, similar to a female
infant with MLS syndrome who also died suddenly at
4 months of age [42].
The combination of clinical features in patient 2
clearly is at the severe end of the phenotypic spectrum
in MLS syndrome. At the other end, no obvious MLS-
typical sign has been observed in the three HCCS-muta-
tion positive female relatives of patient 1. Although we
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at birth in the mother, maternal aunt and grandmother
of patient 1, non-penetrance in females with HCCS mu-
tation or Xp22.2 monosomy has already been described
[4,14]. In an Ashkenazi family, the index case and her
sister showed eye anomalies and/or aplastic skin defects.
The two sisters and their mother, who did not show any
apparent sign of MLS carried the same small deletion in
HCCS [4]. The same large terminal Xp deletion encom-
passing HCCS has been detected in a healthy female and
her MLS-affected daughter, however, the mother was
found to be a mosaic with 45,X[11]/46,X,del(X)(p22.2)
[89] [14]. Thus, sex chromosome mosaicism may help to
prevent the development of MLS-characteristic features
in females and explain, at least in part, the high degree
of inter- and intrafamiliar phenotypic variability [11,14].
In line with this, patient 3 who had unilateral ocular
anomalies and no skin defects turned out to be a mosaic
for a 2-bp HCCS deletion (c.[=/524_525delAG]). While
this frameshift mutation was prominent in DNA from
buccal cells, detailed analysis of leukocyte-derived DNA
indicated a mixture of cells either carrying one wild-type
and one mutant allele (~52%) or two wild-type alleles
(~48%). Mosaicism was further confirmed by absence of
the c.524_525delAG mutation in LCL-derived DNA of
patient 3. For lymphoblastoid cell lines, rapid progression
from polyclonality to pauciclonality or even monoclonality
during cell culturing has been described [23,24]. Thus,
clonal evolution likely accounts for disclosure of only
HCCS wild-type sequence in DNA isolated from patient’s
3 in vitro LCL culture (Figure 3B). Indeed, about 20% of
established LCLs is affected by pauciclonality/monoclonal-
ity indicating that outgrowth of a single clone of fast-
growing B lymphocytes is a common phenomenon in
cultured LCLs [23,24]. The apparently variable degree
of mosaicism in different tissues of patient 3 might have
contributed to her attenuated phenotype. Nevertheless,
in a female infant with classical MLS and mosaic com-
plex X-chromosomal rearrangements [43], mosaicism
did not contribute to a mild phenotype indicating that
other mechanisms account for the high clinical variabil-
ity in females with HCCS null allele.
XCI has been discussed to contribute to phenotypic
variability in MLS-affected females [17], including minor
or no clinical signs. The X inactivation process starts
about the time of late blastocyst or early gastrulation
and inactivates one of the two X chromosomes, inde-
pendent of the parental origin. The differential activity
of the two X chromosomes is stably transmitted to all
the descendants of a single cell and gives rise to cellular
mosaicism in females [44]. Unequal inactivation of the
parental alleles is known as skewing and can be the re-
sult of two different mechanisms. First, stochastic factors
can cause non-random XCI in the early embryo, especiallywhen the pool of precursor cells is limited. Secondary or
acquired skewed XCI is the result of cell selection down-
stream of the X inactivation process [44,45]. In female car-
riers with Xp22 monosomy or an HCCS mutation, cells
with an active aberrant X chromosome undergo severe
respiratory problems due to disturbed mitochondrial
OXPHOS as shown in yeast [4,37]. Impairment of the
MRC is accompanied by a decrease in yeast chrono-
logical life span indicating that loss of HCCS negatively
affects cell survival [37]. This finding suggests that cells
with an active wild-type X chromosome reproduce fas-
ter and eventually outgrow cells expressing the HCCS
mutation-bearing X chromosome leading to elimination
of mutant cells and unbalanced/skewed XCI. Indeed, a
remarkable regenerative capacity has been demon-
strated in healthy cardiomyocytes of female mice with
heart-specific inactivation of one Hccs gene copy. Hyper-
proliferation of healthy cardiac cells efficiently compen-
sates for loss of 50% of Hccs-deficient cells at a time after
XCI has been completed to ensure the formation of a
functional heart [46]. Thus, proliferative advantage of cells
with the normal X chromosome active that leads to in-
creased expansion of the normal cell population may
ameliorate the effects of HCCS deficiency and decrease
the likelihood of symptoms as also seen in female carriers
of severe X-linked disorders and extremely skewed XCI,
such as ATR-X and Wiscott-Aldrich syndrome [47,48].
Consequently, HCCS mutation-positive females with no
apparent MLS sign, exemplified by the three healthy fe-
male relatives of patient 1, are possibly the most favorable
outcome of an effective overgrowth of cells expressing the
normal X-linked allele. This demonstrates a great ability of
the various tissues and organs to successfully eliminate
HCCS-deficient dying cells during embryogenesis. In ac-
cordance with this, the cardiac phenotype in female mice
with heart-specific Hccs deficiency primarily depends on
the high proliferative capacity of the healthy cardiac cells
(with the normal X chromosome active) [46].
Nevertheless, Xp22 monosomy or a heterozygous HCCS
mutation bears the danger of developing MLS syndrome-
typical features raising the question “why is this so?”.
HCCS deficiency has been demonstrated to impair the
MRC and induces overproduction of reactive oxygen spe-
cies (ROS) [37]. The different ability of developing tis-
sues and organs to cope with cells harbouring a
defective OXPHOS system (as a result of an active mu-
tant X chromosome) may account for the high clinical
variability in MLS syndrome and could explain some
specific clinical features, such as (histioctyoid) cardio-
myopathy [49], agenesis of the corpus callosum [50],
and deafness which are typically found in OXPHOS
disorders [8,51]. In line with this, cardiomyopathy, ven-
tricular dilation as well as various pathologies of the
cardiac conduction system and sudden cardiac death
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been explained by the amount and localization of re-
sidual diseased tissue in the heart at birth [46]. However,
microphthalmia/anophthalmia, sclerocornea, microceph-
aly and linear skin defects are not usually found in mito-
chondrial diseases [8] and are unlikely to be caused by
primary OXPHOS defects. Implication of mature cyto-
chrome c, the final product of the holocytochrome c-type
synthase (HCCS) reaction, in the mitochondria-dependent
cell death pathway has led to the hypothesis that the in-
ability of HCCS-deficient cells to undergo cytochrome c-
mediated apoptosis may direct cell death towards necrosis
[4]. However, the recent discovery that MRC inhibition
and enhanced ROS levels elicit a dramatic increase in
caspase-dependent apoptosis in eyes and brain of hccs-
deficient medaka fish may explain microphthalmia and CNS
defects in MLS-affected patients [37]. The variable MLS
phenotypes have been proposed to result from the differ-
ent molecular responses of various tissues and organs
on MRC impairment, enhanced ROS production and/
or increased cell death [37]. It has been hypothesized
that the particular involvement of neural crest cells ex-
plains linear skin defects restricted to the face and neck
[11,25] and ocular anomalies. Indeed, extensive apop-
tosis leading to deficiency of neural crest cells has been
shown to cause anophthalmia/microphthalmia upon
influenza B virus infection during early chicken and
mouse embryogenesis [52].
In summary, skewing of the XCI ratio in females with
loss-of-function HCCS mutation represents the end-
point of a cell selection process during embryogenesis.
These selection biases that occurred after primary XCI
have been shown to similarly affect hematopoietic and
epithelial cells suggesting that loss of some X-linked
genes affects cellular growth in different cellular line-
ages in the same way [53]. The combination of (i) stochas-
tic events during establishment of XCI, (ii) the genetic
background, and (iii) secondary cell selection mechanisms
comprising OXPHOS defects with or without enhanced
cell death as the main effect has detrimental impact on
specific developing organs/tissues and likely determines
the phenotypic outcome in females with an HCCS
null allele.Conclusions
Mutation or copy number loss of HCCS is associated with
a wide phenotypic spectrum ranging from no clinical signs
to in utero lethality of MLS syndrome. Somatic mosaicism
could be one factor contributing to a variable phenotype,
however, cell selection mechanisms including OXPHOS
defect and/or enhanced cell death upon HCCS deficiency
likely underlie the great clinical variability in this rare neu-
rocutaneous disorder.Additional file
Additional file 1: Figure S1. Copy number analysis of HCCS exons 1, 3,
4, and 6 on genomic of patient 5 and her parents. qPCR analysis revealed
values that were comparable to a haploid sample (black bars) for patient
5 (orange bars) and her father (blue bars), while values of her mother
(red bars) were comparable to a diploid sample (white bars). Each bar
represents the mean ± SD of at least two experiments, each performed
in duplicate. Figure S2. Delineation of the Xp22.2 deletion breakpoints in
patient 1. FISH with fosmid clones out of Xp22.2 (red) and the X centromere
probe DXZ1 (green) hybridized to lymphocyte metaphase spreads of
patient 1. A. G248P86973A3 showed signals (red) on both X chromosomes.
B. FISH with G248P89648H11 revealed only one signal (red) on the
wild-type X chromosome. C. G248P82946A7 gave signals (red) on one
X chromosome. D. FISH with G248P8046H9 revealed signals on both
the deleted and the wild-type X chromosome. Chromosomes were
counterstained with DAPI. Figure S3. Copy number analysis of HCCS
exons 2-7 on genomic of patient 1. qPCR analysis revealed values that
were comparable to a haploid sample (grey bars) for patient 1 (black bars).
Values of a diploid sample are indicated by white bars. Each bar represents
the mean ± SD of at least three experiments, each performed in duplicate.
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